

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>KIRSKÉ DAVID</u> (Last) (First) (Middle) C/O CTI BIOPHARMA CORP. 3101 WESTERN AVE., SUITE 800 (Street) SEATTLE WA 98121 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CTI BIOPHARMA CORP [CTIC]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) EVP, Chief Financial Officer
	3. Date of Earliest Transaction (Month/Day/Year) 09/29/2022	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
common stock	09/29/2022		M		800	A	\$0.9489	17,713	D	
common stock	09/29/2022		S ⁽¹⁾		800	D	\$6	16,913	D	
common stock	09/29/2022		M		100	A	\$0.9489	17,013	D	
common stock	09/29/2022		S ⁽¹⁾		100	D	\$6.01	16,913	D	
common stock	09/30/2022		M		139,841	A	\$0.9489	156,754	D	
common stock	09/30/2022		S ⁽¹⁾		139,841	D	\$6.0465 ⁽²⁾	16,913	D	
common stock	10/03/2022		M		300	A	\$0.9489	17,213	D	
common stock	10/03/2022		S ⁽¹⁾		300	D	\$6.25	16,913	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-Qualified Stock Option (right to buy)	\$0.9489	09/29/2022		M			800	(3)	02/19/2029	Common Stock	800	\$0	466,608	D	
Non-Qualified Stock Option (right to buy)	\$0.9489	09/29/2022		M			100	(3)	02/19/2029	Common Stock	100	\$0	466,508	D	
Non-Qualified Stock Option (right to buy)	\$0.9489	09/30/2022		M			139,841	(3)	02/19/2029	Common Stock	139,841	\$0	326,667	D	
Non-Qualified Stock Option (right to buy)	\$0.9489	10/03/2022		M			300	(3)	02/19/2029	Common Stock	300	\$0	326,367	D	

Explanation of Responses:

- This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$6.00 to \$6.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

David Kirske

10/03/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.